Histone Deacetylase 1 Expression and Regulatory Network in Lung Adenocarcinoma Based on Data Mining and Implications for Targeted Treatment

Abstract

Background and Aims. Histone deacetylase 1 (HDAC1) codes a protein that is a component of the histone deacetylase complex. The abnormal expression of HDAC1 is strongly correlated with cell proliferation, differentiation, transcription, and translation. Through continuous screening of genes associated with changes in lung adenocarcinoma (LUAD), gene networks are formed to explore tumor pathogenesis and new therapeutic targets. Methods. We evaluated HDAC1 gene survival analysis and its expression of LUAD using relevant websites and databases (TCGA and GEO databases). Through data mining, we determined the frequency and type of HDAC1 mutation, obtained the relevant heat map of the gene interaction network, completed the analysis of gene ontology and function enrichment, and understood the pharmaceutic of HDAC1. Results. We found that HDAC1 expression was associated with the prognosis of patients with LUAD. In gene expression analysis, HDAC1 was highly expressed in LUAD, and the HDAC1 interaction gene network (MARCKSL, eIF3I) was closely related to cellular gene expression. Functional network analysis shows that the expression of HDAC1 is related to the monitoring point of the G1-S phase of the cell cycle and the activation of the Notch signaling pathway (CSL transcription factor), which is involved in the process of cell proliferation and differentiation and gene expression associated with new therapeutic targets. Conclusion. Our data revealed the expression and potential regulatory factors of HDAC1 in LUAD of data mining, which laid a foundation for the study of the occurrence, development, and treatment of HDAC1 in LUAD.

Correlation between chromatin epigenetic-related lncRNA signature (CELncSig) and prognosis, immune microenvironment, and immunotherapy in non-small cell lung cancer

“…Over the past decades, various techniques have been employed to treat NSCLC, including surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. In immunotherapy, standard protocols emphasize immune checkpoint inhibitors, such as Keytruda and Opdivo, which target PD-1 or PD-L1 to activate the patient's immune system [36]. However, immunotherapy is not suitable for all patients, and the effectiveness of immunotherapy depends on PLOS ONE multiple factors, for example, the infiltrating of immune cells, the expression level of immune checkpoint genes, and somatic mutation status [37].…”

HDAC-an important target for improving tumor radiotherapy resistance

“…HDACi plays an anti-cancer role mainly by targeting Class I, II and IV HDACs to regulate histone acetylation status, thereby changing the tumor microenvironment, inhibiting the transmission of tumor related signal pathways, inhibiting tumor cell cycle and inducing apoptosis, and enhancing the killing of immune cells to tumors. Due to the high metabolic characteristics of tumor cells, HDACi has a higher uptake concentration in non-solid tumor cells, but the drug concentration in solid tumor tissue is relatively low, possibly due to the anti-angiogenic effect of HDACi, which leads to insufficient blood supply in solid tumor tissue ( 188 , 189 ). Dual or multi target delivery may help solve the problem of low uptake of HDACi in solid tumors.…”